The premier ice hockey competition, the National Hockey League (NHL) has signed a commercial accord with the pain relief brand, Tylenol.
According to the contract, Tylenol has been named the official pain, cold, and flu symptom relief partner of the NHL.
With the help of this arrangement, to “connect the brand with the NHL and its fans” via the league’s marketing, digital, and social media platforms, Tylenol, which is owned by the Kenvue firm, has now been granted several exclusive marketing rights.
In early February, the NHL’s 2024 fan expo will take place, and on February 3 in Toronto, the brand will be present at the All-Star Game. Even during the 2023-24 Stanley Cup Playoffs later this year, Tylenol will be promoted.
Additionally, utilising the affiliation between the two organisations, a brand campaign will also be launched on NHL digital platforms, in-store retail displays throughout Canada, and other venues.
Chris Falkiner, Vice President of Business Development Solutions, commented, “We are thrilled to welcome Tylenol, an iconic global brand, to the NHL family, so we can work together on building creative programs to engage fans and consumers in Canada. We look forward to launching our efforts together and developing new and unique content that deepens NHL fans’ affinity to Tylenol.”
Andrew Kalmuk, Kenvue’s Vice President of Consumer Demand Generation, said, “Having Tylenol® as the official pain, cold and flu symptom relief partner of the NHL is a way to show Canadians that there are fast, effective, and trusted solutions to relieve your symptoms and help you get back to the sport you love.”